Previous Close | 4.87 |
Open | 4.90 |
Bid | 5.48 x 100 |
Ask | 5.53 x 100 |
Day's Range | 4.90 - 5.51 |
52 Week Range | 2.25 - 7.99 |
Volume | |
Avg. Volume | 211,156 |
Market Cap | 140.171M |
Beta (5Y Monthly) | 0.60 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.94 |
Earnings Date | May 10, 2024 - May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.40 |
Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to the employment of one individual whose employment commenced in March 2024.
Revenue Falls Short While R&D Expenses Decrease Compared to Analyst Estimates
Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023.